These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 34831139)

  • 1. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
    Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
    von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
    J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.
    Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
    Cell Death Dis; 2013 Oct; 4(10):e875. PubMed ID: 24157869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
    Tarantelli C; Gaudio E; Arribas AJ; Kwee I; Hillmann P; Rinaldi A; Cascione L; Spriano F; Bernasconi E; Guidetti F; Carrassa L; Pittau RB; Beaufils F; Ritschard R; Rageot D; Sele A; Dossena B; Rossi FM; Zucchetto A; Taborelli M; Gattei V; Rossi D; Stathis A; Stussi G; Broggini M; Wymann MP; Wicki A; Zucca E; Cmiljanovic V; Fabbro D; Bertoni F
    Clin Cancer Res; 2018 Jan; 24(1):120-129. PubMed ID: 29066507
    [No Abstract]   [Full Text] [Related]  

  • 5. PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma.
    Cao J; Zeng K; Chen Q; Yang T; Lu F; Lin C; Zhan J; Ma W; Zhou T; Huang Y; Luo F; Zhao H
    Cell Death Dis; 2024 Mar; 15(3):237. PubMed ID: 38555280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
    PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
    Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
    FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
    Weigelt B; Warne PH; Lambros MB; Reis-Filho JS; Downward J
    Clin Cancer Res; 2013 Jul; 19(13):3533-44. PubMed ID: 23674493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
    Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
    Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
    Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ginkgolic acid induces apoptosis and autophagy of endometrial carcinoma cells via inhibiting PI3K/Akt/mTOR pathway in vivo and in vitro.
    Zhou L; Li S; Sun J
    Hum Exp Toxicol; 2021 Dec; 40(12):2156-2164. PubMed ID: 34132136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
    Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
    Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
    Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
    Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
    Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
    Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
    Chen J; Zhao KN; Li R; Shao R; Chen C
    Curr Med Chem; 2014; 21(26):3070-80. PubMed ID: 24735369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.
    Lin Q; Chen H; Zhang M; Xiong H; Jiang Q
    Biomed Pharmacother; 2019 Jul; 115():108939. PubMed ID: 31079003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
    Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/mTORC1/2 inhibitor PQR309 inhibits proliferation and induces apoptosis in human glioblastoma cells.
    Yang K; Tang XJ; Xu FF; Liu JH; Tan YQ; Gao L; Sun Q; Ding X; Liu BH; Chen QX
    Oncol Rep; 2020 Mar; 43(3):773-782. PubMed ID: 32020210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.